Stopping or reporting early for positive results in randomized clinical trials: The national cancer institute cooperative group experience from 1990 to 2005

Journal of Clinical Oncology

Volumn 27, Issue 10, 2009, Pages 1712-1721

  Korn, Edward L ^a   Freidlin, Boris ^a   Mooney, Margaret ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; CALCIUM; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; FLUDARABINE; FLUOROURACIL; FLUTAMIDE; FOLINIC ACID; GOSERELIN; IRINOTECAN; LETROZOLE; LEVAMISOLE; MERCAPTOPURINE; METHOTREXATE; OXALIPLATIN; PACLITAXEL; PLACEBO; PLATINUM; PREDNISONE; RETINOIC ACID; RITUXIMAB; TAMOXIFEN; TENIPOSIDE; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; B CELL LEUKEMIA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL EVALUATION; CLINICAL PROTOCOL; CLINICAL TRIAL; COLON ADENOCARCINOMA; COMPARATIVE STUDY; CONTINUOUS INFUSION; DRUG DESIGN; DRUG MEGADOSE; ESOPHAGUS CARCINOMA; FOLLOW UP; HODGKIN DISEASE; HUMAN; INFORMATION PROCESSING; NASOPHARYNX CARCINOMA; NATIONAL HEALTH ORGANIZATION; NONHODGKIN LYMPHOMA; OPTIMISM; PERITONEUM CANCER; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROFESSIONAL STANDARD; PROMYELOCYTIC LEUKEMIA; PROSTATE ADENOCARCINOMA; RANDOMIZED CONTROLLED TRIAL; RECTUM CARCINOMA; REVIEW; SYSTEMATIC ERROR; THERAPY EFFECT; UTERINE CERVIX CARCINOMA;

CLINICAL TRIALS DATA MONITORING COMMITTEES; HUMANS; NATIONAL CANCER INSTITUTE (U.S.); RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; TREATMENT OUTCOME; UNITED STATES;

EID: 63749110127     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.19.5339     Document Type: Review

References (75)

1. Montori VM, Devereaux PH, Adhikari NKJ, et al: Randomized trials stopped early for benefit: A systematic review. JAMA 294:2203-2209, 2005
2. Mueller PS, Montori VM, Bassler D, et al: Ethical issues in stopping randomized trials early because of apparent benefit. Ann Intern Med 146: 878-881, 2007
3. Bassler D, Montori VM, Briel M, et al: Early stopping of randomized clinical trials for overt efficacy is problematic. J Clin Epidemiol 61:241-246, 2008
4. Wilcox RA, Djulbegovic B, Guyatt GH, et al: Randomized trials in oncology stopped early for benefit. J Clin Oncol 26:18-19, 2008
5. Trotta F, Apolone G, Garattini S, et al: Stopping a trial early in oncology: For patients or for industry? Ann Oncol 19:1347-1353, 2008
6. Pater JL, Goss P, Meyer R: Stopping trials for benefit can (sometimes) benefit patients. J Clin Oncol 16:2787-2788, 2008
7. Moertel CG, Fleming TR, Macdonald JS, et al: Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322:352-358, 1990
8. Moertel CG, Fleming TR, Macdonald JS, et al: Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: A final report. Ann Intern Med 122:321-326, 1995
9. Herskovic A, Martz K, al-Sarraf M, et al: Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 326:1593-1598, 1992
10. Cooper JS, Guo MD, Herskovic A, et al: Chemoradiotherapy of locally advanced esophageal cancer: Long-term follow-up of a prospective randomized trial (RTOG 85-01). JAMA 281:1623-1627, 1999
11. Lauer SJ, Toledano S, Winick N, et al: A comparison of early intensive methotrexate/mercap-topurine (MTX/MP) vs early intensive alternating chemotherapy for high-risk acute lymphoblastic leukemia (HR-ALL): A Pediatric Oncology Group (POG) randomized phase III study. Proc Am Soc Clin Oncol 14:342, 1995 (abstr A1030)
12. Lauer SJ, Shuster JJ, Mahoney DH, et al: A comparison of early intensive methotrexate/mercap-topurine with early intensive alternating combination chemotherapy for high-risk B-precursor acute lym- phoblastic leukemia: A Pediatric Oncology Group phase III randomized trial. Leukemia 15:1038-1045, 2001
13. Fetting J, Gray R, Abeloff M, et al: CAF vs a 16-week multidrug regimen as adjuvant therapy for receptor-negative, node-positive breast cancer: An intergroup study. Proc Am Soc Clin Oncol 14:96, 1995 (abstr A83)
14. Fetting JH, Gray R, Fairclough DL, et al: Sixteen-week multidrug regimen versus cyclophos- phamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive, receptor-negative breast cancer: An Intergroup study. J Clin Oncol 16:2382-2391, 1998
15. Rai KR, Peterson B, Kolitz J, et al: Fludarabine induces a high complete remission rate in previously untreated patients with active chronic lymphocytic leukemia (CLL): A randomized inter-group study. Blood 86:A607, 1995 (abstr 2414)
16. Rai KR, Peterson BL, Appelbaum FR, et al:Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 343:1750-1757, 2000
17. Al-Sarraf M, LeBlanc M, Giri PG, et al: Superiority of chemoradiotherapy (CT-RT) vs. radiotherapy (RT) in patients (pts) with locally advanced nasopharyngeal cancer (NPC): Preliminary results of intergroup (0099) (SWOG 8892, RTOG 8817, ECOG 2388) randomized study. Proc Am Soc Clin Oncol 15:313a, 1996 (abstr A882)
18. Al-Sarraf M, LeBlanc M, Giri PG, et al: Che-moradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized Intergroup study 0099. J Clin Oncol 16:1310-1317, 1998
19. Al-Sarraf M, Le Blanc M, Giri P, et al: Superiority of five year survival with chemo-radiotherapy (CT-RT) vs radiotherapy in patients with locally advanced nasopharyngeal cancer (NPC): Intergroup (0099) (SWOG 8892, RTOG 8817, ECOG 2388) phase III study-Final report. Proc Am Soc Clin Oncol 20:227a, 2001 (abstr A905)
20. Tallman MS, Andersen JW, Schiffer CA, et al:All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 337:1021-1028, 1997
21. Nachman JB, Sather HN, Sensel MG, et al:Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med 338:1663-1671, 1998
22. Albain K, Green S, Osborne K, et al: Tamox- ifen (T) versus cyclophosphamide, Adriamycin and 5-FU plus either concurrent or sequential T in post- menopausal, receptor(+), node(+) breast cancer: A Southwest Oncology Group phase III intergroup trial (SWOG-8814, INT-0100). Proc Am Soc Clin Oncol 16:128a, 1997 (abstr A450)
23. Albain K, Barlow W, O'Malley F, et al: Concurrent (CAFT) versus sequential (CAF-T) chemohor- monal therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen) versus T alone for postmenopausal, node-positive, estrogen (ER) and/or progesterone (PgR) receptor-positive breast cancer: Mature outcomes and new biologic correlates on phase III intergroup trial 0100 (SWOG-8814). Breast Cancer Res Treat 90:195, 2005 (abstr A37)
24. Peters WA, Liu PY, Barrett R, et al: Cisplatin, 5-fluorouracil plus radiation therapy are superior to radiation therapy as adjunctive therapy in high-risk, early stage carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: Report of a phase III intergroup study. Gynecol Oncol 72:443, 1999 (abstr A1)
25. Peters WA 3rd, Liu PY, Barrett RJ 2nd, et al:Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 18:1606-1613, 2000
26. Henderson IC, Berry D, Demetri G, et al: Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (PTS) with node-positive primary breast cancer. Proc Am Soc Clin Oncol 17:101a, 1998 (abstr 390)
27. Henderson IC, Berry DA, Demetri GD, et al:Improved outcomes from adding sequential pacli-taxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976-983, 2003
28. George SI, Green MR: Controversies in the earlyreportingofa clinicaltrialin earlybreastcancer, in DeMets DL, Furberg CD, Friedman LM (eds):Data Monitoring in Clinical Trials. New York, NY, Springer, 2006, pp 346-359
29. Morris M, Eifel PJ, Lu J, et al: Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 340:1137-1143, 1999
30. Eifel PJ, Winter K, Morris M, et al: Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: An update of Radiation Therapy Oncology Group trial (RTOG) 90-01. J Clin Oncol 22:872-880, 2004
31. Nachman JB, Sposto R, Herzog P, et al: Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol 20:3765-3771, 2002
32. Press OW, LeBlanc M, Lichter A, et al: A phase III randomized intergroup trial of subtotal lymphoid irradiation (STLI) versus doxorubicin, vinblastine, and STLI for stage IA-IIA Hodgkin's disease (SWOG 9133, CALGB 9391). Blood 96:575a, 2000 (abstr A2471)
33. Press OW, LeBlanc M, Lichter AS, et al: Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. J Clin Oncol 19:4238-4244, 2001
34. Roach M III, DeSilvio M, Lawton C, et al: Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 21:1904-1911, 2003
35. Lawton CA, DeSilvio M, Roach M 3rd, et al: An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: Updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys 69:646-655, 2007
36. Roach M III, Lu JD, Lawton C, et al: A phase III trial comparing whole-pelvic (WP) to prostate only (PO) radiotherapy and neoadjuvant to adjuvant total androgen suppression (TAS): Preliminary analysis of RTOG 9413. Int J Radiat Oncol Biol Phys 51:3, 2001 (suppl; abstr plenary 5)
37. Markman M, Liu PY, Wilczynski S, et al: Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 21:2460-2465, 2003
38. Markman M, Liu P, Wilczynski S, et al: Survival (S) of ovarian cancer (OC) patients (pts) treated on SWOG9701/GOG178: 12 versus (v) 3 cycles (C) of monthly single-agent paclitaxel (PAC) following attainment of a clinically-defined complete response (CR) to platinum (PLAT)/PAC. J Clin Oncol 24:257s, 2006 (suppl; abstr 5005)
39. Goldberg RM, Morton RF, Sargent DJ, et al:N9741: Oxaliplatin (oxal) or CPT-11 + 5-fluorouracil (5FU)/leucovorin (LV) or oxal + CPT-11 in advanced colorectal cancer (CRC)-Initial toxicity and response data from a GI Intergroup study. Proc Am Soc Clin Oncol 21:128a, 2002 (abstr 511)
40. Goldberg RM, Sargent DJ, Morton RF, et al: A randomized controlled trial of fluorouracil plus leuco- vorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colo- rectal cancer. J Clin Oncol 22:23-30, 2004
41. Goss PE, Ingle JN, Martino S, et al: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793-1802, 2003
42. Goss PE, Ingle JN, Martino S, et al: Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA. 17. J Natl Cancer Inst 97:1262-1271, 2005
43. Hochster HS, Weller E, Ryan T, et al: Results of E1496: A phase III trial of CVP with or without maintenance rituximab in advanced indolent lym- phoma (NHL). J Clin Oncol 22:558s, 2004 (suppl 14;abstr 6502)
44. Hochster HS, Weller E, Gascoyne RD, et al: Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma (FL): Results of the E1496 phase III trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B. Blood 106:106a, 2005 (abstr 349)
45. Rajkumar SV, Blood E, Vesole DH, et al: A randomised phase III trial of thalidomide plus dexa-methasone versus dexamethasone in newly diagnosed multiple myeloma (E1A00): A trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 22:560s, 2004 (suppl; abstr 6508)
46. Rajkumar SV, Blood E, Vesole D, et al: Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 24:431-436, 2006
47. Seibel NL, Steinherz PG, Sather HN, et al:Early treatment intensification improves outcome in children and adolescents with acute lymphoblastic leukemia (ALL) presenting with unfavorable features who show a rapid early response (RER) to induction chemotherapy: A report of CCG1961. Blood 102: 224A-225A, 2003 (abstr 787)
48. Seibel NL, Steinherz PG, Sather HN, et al:Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: A report from the Children's Oncology Group. Blood 111:2548-2555, 2008
49. Giantonio BJ, Catalano PJ, Meropol NJ, et al:High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. J Clin Oncol 23:1s, 2005 (suppl; abstr 2)
50. Giantonio BJ: ECOG-E3200: FOLFOX4 with bevacizumab versus FOLFOX4 versus bevacizumab in patients with previously treated advanced colo- rectal cancer. Colorectal Cancer Update 4:18-21, 2005
51. Giantonio BJ, Catalano PJ, Meropol NJ, et al:Bevacizumab in combination with oxaliplatin, flu- orouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:1539-1544, 2007
52. Flinn IW, Kumm E, Grever MR, et al: Fludara-bine and cyclophosphamide produces a higher complete response rate and more durable remissions than fludarabine in patients with previously untreated CLL: Intergroup trial E2997. Blood 104:139a, 2004 (abstr 475)
53. Flinn IW, Neuberg DS, Grever MR, et al:Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol 25:793-798, 2007
54. Romond EH, Perez EA, Bryant J, et al: Tras- tuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684, 2005
55. Perez E, Romond E, Suman V, et al: Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. J Clin Oncol 25:6s, 2007 (suppl; abstr 512)
56. Sandler A, Gray R, Perry MC, et al: Paclitaxel- carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550, 2006
57. Miller KD, Wang M, GralowJ, et al: A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: A trial coordinated by the Eastern Cooperative Oncology Group (E2100). Breast Cancer Res Treat 94:S6, 2005 (suppl 1; abstr 3)
58. Miller K, Wang M, Gralow J, et al: Paclitaxel plus bevacizumab versus paclitaxel alone for meta- static breast cancer. N Engl J Med 357:2666-2676, 2007
59. Burnell MJ, Levine MN, Chapman JA, et al: A phase III adjuvant trial of sequenced EC + filgrastim + epoetin-alpha followed by paclitaxel compared to sequenced AC followed by paclitaxel compared to CEF in women with node-positive or high-risk node- negative breast cancer (NCIC CTG MA. 21). J Clin Oncol 25:15s, 2007 (suppl; abstr 550)
60. Burnell M, Levine M, Chapman JA, et al: A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by pacli-taxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA. 21: Results of an interim analysis. 29th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 14-17, 2006 (abstr A53)
61. Cannistra SA: The ethics of early stopping rules: Who is protecting whom? J Clin Oncol 22:1542-1545, 2005
62. Pater J, Goss P, Ingel J, et al: The ethics of early stopping rules. J Clin Oncol 23:2862-2863, 2005
63. Bukowski RM, Eisen T, Szczylik C, et al: Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: Survival and bi- omarker analysis. J Clin Oncol 25:240s, 2007 (suppl;abstr 5023)
64. Peto R, Pike MC, Armitage P, et al: Design and analysis of randomized clinical trials requiring prolonged observation of each patient: I. Introduction and design. Br J Cancer 34:535-612, 1976
65. O'Brien PC, Fleming TR: A multiple testing procedure for clinical trials. Biometrics 35:549-556, 1979
66. Pocock SJ, Hughes MD: Practical problems in interim analyses, with particular regard to estimation. Control Clin Trials 10:209S-221S, 1989
67. Fan X, DeMets DL, Lan KKG: Conditional bias of point estimates following a group sequential test. J Biopharm Stat 14:505-530, 2004
68. Goodman SN: Stopping at nothing? Some dilemmas of data monitoring in clinical trials. Ann Intern Med 146:882-887, 2007
69. Freidlin B, Korn EL: Stopping clinical trials early for benefit: Implact on estimation. Clin Trials (in press)
70. Wheatley K, Clayton D: Be skeptical about unexpected large apparent treatment effects: The case of an MRC AML12 randomization. Control Clin Trials 24:66-70, 2003
71. Korn EL, Freidlin B, George SL: Data monitoring and large apparent treatment effects. Control Clin Trials 25:67-69, 2004
72. Clayton D, Wheatley K: Reply to the letter of Korn, et al. Control Clin Trials 25:71-72, 2004
73. Spiegelhalter DJ, Freedman LS, Parmar MKB: Bayesian approaches to randomized trials. J R Stat Soc A 157:357-387, 1994
74. Strauss GM, Herndon JE II, Maddaus MA, et al: Adjuvanct paclitaxel plus carboplatin compared with observation in stage 1B non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 31:5043-5051, 2008
75. Strauss GM, Herndon J, Maddaus MA, et al:Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage 1B non-small cell lung cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) protocol 9633. J Clin Oncol 22:621s, 2004 (suppl; abstr 7019)